Preventative cancer care and proactive healthcare are changing fast. In the past, medicine was mostly reactive. Doctors usually tested people only after they showed symptoms of being sick. Now, new proactive cancer screening tools like molecular diagnostics, artificial intelligence, and advanced imaging are shifting focus. The goal is to catch diseases early, before patients feel sick. A key part of this change is blood-based screening assays, often called liquid biopsies. These tests look for signs of cancer in the blood long before a physical tumor can be seen.
On July 27, 2026, the FDA approved SimpleScreen CRC. This is a blood test for colorectal cancer (CRC) screening made by a company called Freenome. This approval gives people more choices for non-invasive screening. It also shows that patients and doctors want easy, proactive healthcare options.
At the same time, doctors are using more whole-body tests, like whole-body magnetic resonance imaging (MRI). This shows a growing demand for complete health checks that look at the whole body, not just one organ.
This article looks at the data, technology, and market impact of the FDA approval for SimpleScreen CRC. It also compares this liquid biopsy to other CRC screening choices and new treatments. Finally, it looks at the bigger trend of proactive whole-body health screening.
The Epidemiological Burden of Colorectal Cancer
Colorectal cancer is the second-leading cause of cancer deaths in the United States. The disease usually starts as harmless polyps. Over ten to fifteen years, these polyps collect genetic changes and turn into cancer. Because it grows slowly, colorectal cancer is easy to prevent and treat if found early.
Even though we have good screening tools, many people don’t get tested. Roughly 45 to 48 million eligible Americans are currently overdue for colorectal cancer screening — a number that climbs to nearly 60 million when including those due for rescreening within the year. As a result, the disease is expected to kill more than 55,000 people in the U.S. in 2026 alone. Experts believe 90% of these deaths could be prevented with early action.1
Making things worse, colorectal cancer is rising in younger adults. Cases in people under 50 have been going up for years. Researchers think this is due to environment, diet, and hidden genetics. Standard rules don’t recommend regular screenings for average-risk people under 45. So, doctors are looking at new blood tests to help diagnose younger, symptom-free people.
Traditional screenings have big barriers. Patients dislike the colon prep and sedation needed for a colonoscopy. Many also avoid handling stool for at-home tests. Because of this, we need simple blood tests that can be done during regular doctor visits.
Proactive Cancer Screening: Freenome SimpleScreen CRC
Liquid biopsies work by looking at the life cycle of cancer cells. As tumor cells die, they release bits of their DNA into the blood. This is called circulating tumor DNA (ctDNA). It carries unique signs of the original tumor.
Freenome’s SimpleScreen CRC test uses a special platform to study this DNA. Instead of just looking for single mutations, the test looks at DNA methylation. This is a process cells use to turn genes on or off. Abnormal methylation is an early sign of colorectal cancer. The test combines different markers to create a detailed profile of the blood.
Freenome uses artificial intelligence and machine learning (AI/ML) to read this complex data. These programs are trained to spot the tiny signs of cancer hidden among healthy DNA. The test only needs a normal blood draw, which removes the fear and hassle of other tests. If the result is “positive,” it means cancer signals were found. The patient then needs a colonoscopy to confirm the result.
Clinical Validation: Colon Cancer Blood Test
The FDA approved SimpleScreen CRC based on the PREEMPT CRC study. This is the largest clinical trial ever done for a blood-based colorectal cancer test. It started in 2020 to see how well the test worked on normal-risk people with no symptoms.
Colon Cancer Blood Test Design and Demographics
The trial happened at over 200 sites in 49 U.S. states and the UAE. It included over 48,000 people aged 45 to 85. The study worked with groups like the Colorectal Cancer Alliance and historically Black colleges. This made sure the participants reflected real-world diversity.
People gave a blood sample and then had a normal colonoscopy within 120 days. The blood test results were compared to what doctors found during the colonoscopy. People with a history of cancer, certain bowel diseases, or a recent colonoscopy could not join. The final group had 27,010 people. The average age was 58.1, and the group was 55.8% female and 73.0% White.
Primary Efficacy of SimpleScreen CRC and Performance Metrics
The study’s main goals were to see how sensitive the test was for finding cancer. It also checked how well the test correctly identified healthy people. A secondary goal was to see if it could find advanced precancerous lesions.
Results were published in the Journal of the American Medical Association (JAMA). The test met all its goals. SimpleScreen CRC found cancer with 79.2% sensitivity. It correctly identified healthy people with 91.5% specificity.
Researchers also adjusted the data to match the U.S. population’s age and sex. In this adjusted data, SimpleScreen CRC had 81.1% sensitivity for finding cancer. It had 90.4% specificity for correctly identifying healthy people.
Stage-Specific Detection and the Precancer Challenge
The test’s success depends on the stage of the cancer. Larger tumors shed more DNA into the blood. In adjusted results, the test found 63.5% of Stage I cancers, 100% of Stage II, 80.5% of Stage III, and 100% of Stage IV. For adults aged 45 to 49, the test had an impressive 100% sensitivity.
However, finding precancerous polyps is still hard for blood tests. These polyps don’t have many blood vessels, so they don’t shed much DNA into the blood. The study found only 13.7% (adjusted) of these early lesions. Researchers admit that finding early polyps needs more technical progress.
Iterative Assay Evolution and Next-Generation Performance
Freenome is working hard to improve how well the test finds early polyps. The company recently shared results from an updated version of their test. This new version uses better tools and processes to find much smaller amounts of cancer DNA.
The updated test showed big improvements. It found 18.2% of advanced precancerous lesions. For the highest-risk polyps (high-grade dysplasia), it found 41.9%. Overall cancer detection stayed strong at 80.4%.
Computer models show these updates could greatly help public health. Compared to the first test, this new version could save more lives and prevent more cancer cases. It proves that AI-driven tests can get better over time.
Commercialization Dynamics: The Abbott Partnership
Getting FDA approval led to big business moves for Freenome. Abbott, a massive healthcare company, secured the exclusive rights to sell SimpleScreen CRC in the U.S. under a commercial agreement signed in August 2025. Following the July 2026 FDA approval, that agreement triggered a $100 million milestone payment from Abbott to Freenome, with the test set to launch in fall 2026.
Abbott is using its huge network to sell the test. Because Abbott owns Exact Sciences (makers of Cologuard), they already have great relationships with doctors. They use a digital system called Nexus to check medical records. This system tells doctors when a patient needs a screening so they can offer the blood test right then.
FDA approval also means Medicare will cover the cost of the test. Experts expect the American Cancer Society to officially recommend it soon. Having insurance coverage and official support are essential for the test to become popular.
Comparative Analysis of Non-Invasive Screening Modalities
SimpleScreen CRC is entering a crowded market. Doctors and patients have many choices. These include stool-based tests like FIT and DNA tests, as well as other blood tests.
The Guardant Shield Benchmark
In 2024, a company named Guardant Health got approval for Shield. This was the first blood test for CRC screening. A study of 10,000 people showed Shield found 83.1% of cancers. It correctly identified healthy people 89.6% of the time.
Like Freenome, Shield struggled to find recancerous polyps. It only found 13.2% of them and had a 10.1% false-positive rate. Shield found 65% of Stage I cancers but did better at later stages. Guardant is pushing hard to sell the test by driving mobile labs directly to communities.
Stool-Based Precision: Cologuard Plus
Blood tests are easy, but stool tests are much better at finding early polyps. Exact Sciences recently released Cologuard Plus. This new test looks for DNA and blood in stool. Because polyps shed cells directly into the bowel, their DNA is easy to find in stool.
Cologuard Plus uses advanced markers to find cancer. In studies, it found an amazing 93.9% of cancers. It also found 43.4% of precancerous lesions, and 74% of high-risk ones. The test stayed highly accurate, meaning fewer false alarms. Over ten years, regular testing with Cologuard Plus catches significantly more cancer than older methods.
Modality Efficacy Comparison
The clinical agreement is that a colonoscopy is still the best test. It finds 95% of cancers and can actually remove polyps during the procedure. For people who refuse a colonoscopy, Cologuard Plus is the best non-invasive choice.
Blood tests like SimpleScreen and Shield are for people who hate both colonoscopies and stool tests. The medical belief is that any screening is much better than no screening at all.
Broader Innovations in Colorectal Cancer Management
Better screening is happening alongside huge leaps in cancer treatment. Doctors are now using special targeted therapies and real-time monitoring to fight the disease.
Therapeutic Breakthroughs and Biomarker Integration
The FDA recently approved a new treatment called the BREAKWATER regimen. It combines standard chemotherapy with targeted drugs for advanced colorectal cancer. This shows a big shift toward precision medicine. Targeting specific mutations helps patients live longer and respond better to treatment.
Drug companies are also testing other new combinations. For example, new drugs are being paired together to fight hard-to-treat cancer mutations. Early trials show these new drug combos can control the disease in many heavily pretreated patients.
The Ascendance of ctDNA in Disease Monitoring
Blood tests for tumor DNA aren’t just for finding cancer; they help monitor it too. Doctors use them to check if any cancer is left after surgery. Large studies show that checking the blood over time helps doctors plan the best follow-up care.
If cancer DNA is found after surgery, doctors can increase treatment to help the patient. If the blood is totally clear of cancer DNA, it acts as a “clear stop” signal. This means doctors can safely skip harsh chemotherapy. This saves patients from awful side effects while keeping them safe.
Preventative Lifestyle and Pharmacological Interventions
Beyond drugs and surgery, lifestyle choices and other medicines can lower cancer risk. Studies show that popular weight-loss drugs (GLP-1s) can cut the risk of colon cancer by 51% in patients with bowel disease.
Healthy habits also have proven benefits. Programs that help cancer patients exercise improve their quality of life and save hospitals money. Also, using mobile health apps tripled the number of at-risk cancer survivors who kept up with their screenings. This proves digital tools are vital for modern care.
The Paradigm Shift to Proactive Health: Integrating Whole Body MRI
Blood tests are a massive step forward, but they show a change in what patients want. Modern consumers want to monitor their bodies proactively, rather than wait to get sick. Blood tests like SimpleScreen CRC help stop colon cancer, but they don’t find other silent diseases in the body.
Because of this, people are demanding full-body health checks. Elective whole-body magnetic resonance imaging (MRI) is becoming very popular. Clinics like Bionicc Body Screening in Southfield, Michigan, are leading this new trend.
The Clinical Rationale for Asymptomatic MRI Full Body Screening
Normally, doctors only order an MRI when a patient has clear symptoms like pain. However, many deadly problems, like aneurysms or tumors, grow silently in their early stages. By the time symptoms appear, it might be too late.
A preventative whole-body MRI skips this waiting game. It lets healthy people get a gold-standard scan without needing a doctor’s referral. The goal is to catch problems at Stage 1. Radiologists scan the brain, spine, chest, abdomen, and pelvis to create a detailed baseline of the body. They use this baseline to track changes over time and spot tiny problems before they turn dangerous.
Pathological Scope and Diagnostic Capabilities
Unlike a blood test, a full body MRI lets doctors actually see inside all major organ systems. These scans check for issues in the major organs and tissues. They are incredibly thorough.
For cancer, an MRI is great at finding solid tumors in organs like the liver, kidneys, and thyroid. A blood test might show a problem exists, but an MRI shows exactly where it is. It can spot masses when they are only millimeters in size.
Beyond cancer, the scan checks blood vessels to find silent brain aneurysms. It also looks at soft tissues to find early signs of diseases like multiple sclerosis or fatty liver disease. It can even spot kidney stones and severe spine problems like like herniated discs.
Technological Considerations and the Patient Experience
A major benefit of an MRI is that it does not use harmful radiation. Unlike CT or PET scans, an MRI uses strong magnets and radio waves to create detailed pictures. Because it is radiation-free, it is very safe for people to get regular scans throughout their lives.
Clinics like Bionicc Body Screening focus on making the patient comfortable and the process fast. They use a self-pay model, so patients don’t have to fight with insurance. Patients are scanned in modern “wide bore” machines. These machines have a large opening that stops people from feeling claustrophobic.
The scan takes about 70 minutes, and patients can listen to music to relax. The whole visit takes only 90 minutes. Most importantly, expert radiologists carefully check the high-definition images to find any hidden health threats.
In the end, people choose a full body MRI to gain “peace of mind”. In a stressful world, seeing that your organs are healthy gives you back your power. It lets patients make smart lifestyle changes and get medical help right when they need it.
Conclusion
The FDA approval of Freenome’s SimpleScreen CRC changes how we screen for colorectal cancer. Doctors now have an easy, AI-driven blood test that catches over 80% of invasive colon cancers. It still struggles to find early polyps. Still, big companies like Abbott will make sure this test reaches millions of patients who hate traditional screenings.
At the same time, this new test highlights a bigger shift toward proactive health. Patients want to find hidden diseases in every part of their bodies. Because of this, safe and detailed imaging like whole-body MRI is becoming incredibly useful. By combining targeted blood tests with advanced MRI scans, patients and doctors can work together. This teamwork will set a new standard for early detection, reduce illness, and help people live longer, healthier lives.
Author: Ryan Ringold is the Managing Director and Patient Advocate at Bionicc Body Screening. Continuing the mission of his father, Dr. Warren Ringold, Ryan is dedicated to providing Metro Detroit with direct, referral-free access to gold-standard preventative imaging. By simplifying complex medical data into actionable insights, he empowers individuals to take ownership of their health through early detection.
All content is fact-checked by the Bionicc Clinical Team to ensure medical accuracy. | Published: July 29, 2026
Sources and References
Freenome, Inc. and Abbott. “FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.” Press release, July 27, 2026. https://www.freenome.com/newsroom/fda-approves-freenomes-simplescreen-crc/
American Cancer Society. “Key Statistics for Colorectal Cancer.” 2026. https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html
Ebner DW, Kisiel JB, Fendrick AM, et al. “Estimated Average-Risk Colorectal Cancer Screening-Eligible Population in the US.” JAMA Network Open. 2024;7(3):e245537. doi:10.1001/jamanetworkopen.2024.5537. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2816965
Shaukat A, Burke CA, Chan AT, et al. “Clinical Validation of a Circulating Tumor DNA–Based Blood Test to Screen for Colorectal Cancer.” JAMA. 2025. doi:10.1001/jama.2025.7515. https://pmc.ncbi.nlm.nih.gov/articles/PMC12131177/
Freenome, Inc. “Freenome Reports Top-Line Readout of Updated SimpleScreen™ CRC Colorectal Cancer Screening Blood Test Met All Primary and Secondary Endpoints.” Press release, 2026. https://www.freenome.com/newsroom/freenome-reports-top-line-readout-of-updated-simplescreen-crc-colorectal-cancer-screening-blood-test-met-all-primary-and-secondary-endpoints/
Abbott Laboratories. “Abbott Completes Acquisition of Exact Sciences.” Press release, March 23, 2026. https://abbott.mediaroom.com/2026-03-23-Abbott-completes-acquisition-of-Exact-Sciences
Guardant Health. “Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening.” Press release, July 29, 2024. https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Healths-Shield-Blood-Test-Approved-by-FDA-as-a-Primary-Screening-Option-Clearing-Path-for-Medicare-Reimbursement-and-a-New-Era-of-Colorectal-Cancer-Screening/default.aspx
Chung DC, Gray DM, Singh H, et al. “A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening.” New England Journal of Medicine. 2024;390(11):973-983. https://www.nejm.org/doi/abs/10.1056/NEJMoa2304714
Exact Sciences Corporation. “FDA Approves Exact Sciences’ Cologuard Plus Test.” Press release, October 4, 2024. https://www.exactsciences.com/newsroom/press-releases/fda-approves-exact-sciences-cologuard-plus-test
Pfizer Inc. “U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI® Combination Regimen in First-Line Metastatic Colorectal Cancer.” Press release, 2026. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-grants-full-approval-pfizers-braftovi-combination
American Society of Clinical Oncology. “GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD.” The ASCO Post, June 2026. https://ascopost.com/news/june-2026/glp-1-receptor-agonists-linked-to-lower-colorectal-cancer-risk-in-patients-with-ibd/
Bionicc Body Screening. “Michigan’s First Full Body MRI | Southfield Screening Center.” https://www.bioniccbodyscreening.com/